{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:52:44Z","timestamp":1792155164628,"version":"4.4.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009429","name":"Israel National Road Safety Authority","doi-asserted-by":"publisher","award":["P50 CA221745"],"award-info":[{"award-number":["P50 CA221745"]}],"id":[{"id":"10.13039\/100009429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009429","name":"Israel National Road Safety Authority","doi-asserted-by":"publisher","award":["T32CA082088"],"award-info":[{"award-number":["T32CA082088"]}],"id":[{"id":"10.13039\/100009429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009429","name":"Israel National Road Safety Authority","doi-asserted-by":"publisher","award":["K12 CA184746"],"award-info":[{"award-number":["K12 CA184746"]}],"id":[{"id":"10.13039\/100009429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016945","name":"Sidney Kimmel Center for Prostate and Urologic Cancers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA082088"],"award-info":[{"award-number":["T32CA082088"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K12 CA184746"],"award-info":[{"award-number":["K12 CA184746"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA221745"],"award-info":[{"award-number":["P50 CA221745"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009779","name":"Bladder Cancer Advocacy Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.urolonc.2022.05.013","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T06:27:00Z","timestamp":1657261620000},"page":"398-409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non\u2013muscle invasive bladder cancer"],"prefix":"10.1016","volume":"41","author":[{"given":"Carissa","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Pietzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2022.05.013_bib0001","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bju.12012","article-title":"Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Gu\u00e9rin (BCG): results of an international individual patient data survey (IPDS)","volume":"112","author":"Witjes","year":"2013","journal-title":"BJU international"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0002","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"European Urology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0003","first-page":"0","article-title":"International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Gu\u00e9rin-exposed High-risk Non-muscle-invasive Bladder Cancer","author":"Roumigui\u00e9","year":"2021","journal-title":"European urology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0004","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"The Journal of urology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0005","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update","volume":"76","author":"Babjuk","year":"2019","journal-title":"European urology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0006","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/JU.0000000000001029","article-title":"Health Related Quality of Life of Patients with Bladder Cancer in the RAZOR Trial: A Multi-Institutional Randomized Trial Comparing Robot versus Open Radical Cystectomy","volume":"204","author":"Becerra","year":"2020","journal-title":"The Journal of urology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0007","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.eururo.2021.01.032","article-title":"Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes","volume":"79","author":"Catto","year":"2021","journal-title":"European urology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0008","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.juro.2014.05.115","article-title":"H2O2 generation by bacillus Calmette-Gu\u00e9rin induces the cellular oxidative stress response required for bacillus Calmette-Gu\u00e9rin direct effects on urothelial carcinoma biology","volume":"192","author":"Shah","year":"2014","journal-title":"The Journal of urology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0009","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","article-title":"Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin","volume":"164","author":"Thalmann","year":"2000","journal-title":"Journal of Urology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0010","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Science translational medicine"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0011","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF01741551","article-title":"Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Gu\u00e9rin in superficial bladder cancer","volume":"34","author":"De Boer","year":"1992","journal-title":"Cancer immunology, immunotherapy: CII"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0012","first-page":"199","article-title":"Long-term immunobiological effects of intravesical bacillus Calmette-Gu\u00e9rin against bladder carcinoma recurrences","volume":"77","author":"B\u00f6hle","year":"1992","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0013","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2018.08.015","article-title":"Background and Update for S1602 "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-na\u00efve High-grade Non-muscle-invasive Bladder Cancer","volume":"4","author":"Svatek","year":"2018","journal-title":"European urology focus"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0014","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1614857","article-title":"Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial","volume":"8","author":"Ji","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0015","doi-asserted-by":"crossref","first-page":"18627","DOI":"10.1073\/pnas.2004421117","article-title":"Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-\u03b3 signaling","volume":"117","author":"Antonelli","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0016","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1158\/2326-6066.CIR-21-0285","article-title":"\u03b3\u03b4 T Cells Support Antigen-Specific \u03b1\u03b2 T cell-Mediated Antitumor Responses during BCG Treatment for Bladder Cancer","volume":"9","author":"Ji","year":"2021","journal-title":"Cancer immunology research"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0017","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.4049\/jimmunol.1801022","article-title":"Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer","volume":"202","author":"Leko","year":"2019","journal-title":"Journal of immunology (Baltimore, Md: 1950)"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0018","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"European urology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0019","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0020","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor Mutational Burden and Response Rate to PD-1 Inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0021","first-page":"40","article-title":"Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer","author":"Lv","year":"2020","journal-title":"Bioscience reports"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0022","doi-asserted-by":"crossref","first-page":"39916","DOI":"10.18632\/oncotarget.9537","article-title":"Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Gu\u00e9rin therapy in bladder cancer","volume":"7","author":"Pichler","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0023","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12885-017-3231-7","article-title":"Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder","volume":"17","author":"Miyake","year":"2017","journal-title":"BMC cancer"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0024","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1172\/JCI89717","article-title":"ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence","volume":"127","author":"Chevalier","year":"2017","journal-title":"The Journal of clinical investigation"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0025","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1158\/0008-5472.CAN-18-0173","article-title":"Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy","volume":"78","author":"Saito","year":"2018","journal-title":"Cancer research"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0026","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0027","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","article-title":"Adaptive Immune Resistance to Intravesical BCG in Non\u2013Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials","volume":"26","author":"Kates","year":"2020","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0028","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0029","doi-asserted-by":"crossref","first-page":"34066","DOI":"10.18632\/oncotarget.26122","article-title":"Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin","volume":"9","author":"Hashizume","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0030","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0031","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1200\/JCO.2020.38.15_suppl.5022","article-title":"Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816)","volume":"38","author":"Black","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0032","series-title":"Identification of a novel inflamed tumor microenvironment signature as a predictive biomarker of bacillus Calmette-Guerin immunotherapy in non-muscle invasive bladder cancer. Clinical cancer research: an official journal of the","author":"Damrauer","year":"2021"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0033","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00262-017-2093-9","article-title":"High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients","volume":"67","author":"Breyer","year":"2018","journal-title":"Cancer immunology, immunotherapy: CII"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0034","doi-asserted-by":"crossref","first-page":"75176","DOI":"10.18632\/oncotarget.12661","article-title":"Genomic characterization of high-risk non-muscle invasive bladder cancer","volume":"7","author":"Meeks","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0035","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","article-title":"Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy","volume":"75","author":"Pietzak","year":"2019","journal-title":"European urology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0036","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1158\/0008-5472.CAN-20-0977","article-title":"Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer","volume":"80","author":"Bellmunt","year":"2020","journal-title":"Cancer research"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0037","doi-asserted-by":"crossref","DOI":"10.1007\/s00345-021-03716-3","article-title":"Phase I trial of intravesical Bacillus Calmette-Gu\u00e9rin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Gu\u00e9rin treatment","author":"Alanee","year":"2021","journal-title":"World journal of urology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0038","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1097\/JU.0000000000001576","article-title":"Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model","volume":"205","author":"Kirschner","year":"2021","journal-title":"The Journal of urology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0039","unstructured":"Meeks JJ. Safety and efficacy of first-in-human Phase I study of intravesical pembrolizumab and BCG in BCG-unresponsive NMIBC. Orlando, Florida."},{"key":"10.1016\/j.urolonc.2022.05.013_bib0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS503","article-title":"Sub-urothelial durvalumab injection-1 (SUBDUE-1): A novel approach to immunotherapy for bladder cancer","volume":"39","author":"Viswambaram","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0041","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1158\/1078-0432.CCR-14-0913","article-title":"The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell\u2013Dependent Tumor Immunity","volume":"21","author":"Mangsbo","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0042","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/30996","article-title":"Help for cytotoxic-T-cell responses is mediated by CD40 signalling","volume":"393","author":"Bennett","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0043","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","article-title":"Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody","volume":"25","author":"Vonderheide","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0044","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2326-6066.CIR-13-0067","article-title":"Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer","volume":"2","author":"Sandin","year":"2014","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0045","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/2326-6066.CIR-19-0826","article-title":"CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I\/II-Mediated Manner","volume":"8","author":"Leblond","year":"2020","journal-title":"Cancer Immunology Research"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0046","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd1346","article-title":"Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer","volume":"13","author":"Garris","year":"2021","journal-title":"Science translational medicine"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0047","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ucl.2019.09.013","article-title":"Role of Indoleamine-2,3-Dioxygenase Inhibitors in Salvage Therapy for Non-Muscle Invasive Bladder Cancer","volume":"47","author":"Chu","year":"2020","journal-title":"The Urologic clinics of North America"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0048","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4","volume":"210","author":"Holmgaard","year":"2013","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0049","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1158\/1078-0432.CCR-15-2839","article-title":"Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma","volume":"22","author":"Choueiri","year":"2016","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0050","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1117634","article-title":"Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite","volume":"310","author":"Platten","year":"2005","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0051","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.1073\/pnas.0708809105","article-title":"Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation","volume":"105","author":"Xu","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0052","doi-asserted-by":"crossref","DOI":"10.1186\/2051-1426-2-3","article-title":"Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment","volume":"2","author":"Spranger","year":"2014","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0053","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS5090","article-title":"A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT","volume":"38","author":"Hahn","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0054","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.juro.2011.09.008","article-title":"The FGFR3 mutation is related to favorable pT1 bladder cancer","volume":"187","author":"van Rhijn","year":"2012","journal-title":"The Journal of urology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0055","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nature communications"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0056","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/path.5143","article-title":"FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation","volume":"246","author":"Foth","year":"2018","journal-title":"The Journal of pathology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0057","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1158\/2326-6066.CIR-15-0274","article-title":"Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer","volume":"4","author":"Sweis","year":"2016","journal-title":"Cancer immunology research"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0058","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/1078-0432.CCR-16-2267","article-title":"A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157","volume":"23","author":"Hahn","year":"2017","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0059","unstructured":"Garde D. Sesen Bio trial of cancer drug marked by misconduct and worrisome side effects, documents show. STATNews. https:\/\/www.statnews.com\/2021\/08\/18\/sesen-bio-trial-of-cancer-drug-marked-by-misconduct-documents-show\/2021. Accessed on May 15, 2022."},{"key":"10.1016\/j.urolonc.2022.05.013_bib0060","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1\/Programmed Death Ligand 1 Therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0061","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors","author":"Tagawa","year":"2021","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0062","article-title":"Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin","author":"Chu","year":"2021","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0063","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2018.08.027","article-title":"Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors","volume":"75","author":"Tan","year":"2019","journal-title":"European urology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0064","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.eururo.2021.10.009","article-title":"A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Gu\u00e9rin-exposed Non-muscle-invasive Bladder Cancer","volume":"81","author":"Choi","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0065","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urologic oncology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0066","doi-asserted-by":"crossref","first-page":"28702","DOI":"10.18632\/oncotarget.25614","article-title":"Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus","volume":"9","author":"Oseledchyk","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0067","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0068","first-page":"10","article-title":"The Impact of a New Interleukin-2-Based Immunotherapy Candidate on Urothelial Cells to Support Use for Intravesical Drug Delivery","author":"Schmitz","year":"2020","journal-title":"Life (Basel, Switzerland)"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0069","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2326-6066.CIR-15-0093-T","article-title":"Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models","volume":"4","author":"Rhode","year":"2016","journal-title":"Cancer immunology research"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096705","article-title":"Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion","volume":"9","author":"Gomes-Giacoia","year":"2014","journal-title":"PloS one"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0071","doi-asserted-by":"crossref","first-page":"431-","DOI":"10.1200\/JCO.2022.40.6_suppl.431","article-title":"Positive efficacy and safety phase 3 results in both CIS and papillary cohorts BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) after IL-15R\u03b1Fc superagonist N-803 (Anktiva) and BCG infusion","volume":"40","author":"Chang","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0072","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1577125","article-title":"Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation","volume":"8","author":"Plote","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0073","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon-\u03b12B plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed","volume":"166","author":"O'Donnell","year":"2001","journal-title":"Journal of Urology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0074","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urologic oncology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0076","first-page":"0","article-title":"Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial","author":"Mitra","year":"2021","journal-title":"European urology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0077","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA\/ASCO\/ASTRO\/SUO Guideline","volume":"198","author":"Chang","year":"2017","journal-title":"Journal of Urology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0078","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0079","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0080","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1038\/onc.2008.316","article-title":"Nucleoside analogs: molecular mechanisms signaling cell death","volume":"27","author":"Ewald","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2010.03.028","article-title":"Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model","volume":"76","author":"Horinaga","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0082","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS509","article-title":"A phase I trial of chemoimmunotherapy combining bacillus Calmette-Guerin (BCG) and intravesical gemcitabine for patients with BCG-relapsing high-grade nonmuscle-invasive bladder cancer","volume":"39","author":"De Jesus Escano","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0083","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/ijc.28070","article-title":"Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death","volume":"133","author":"Hodge","year":"2013","journal-title":"International journal of cancer"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0084","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"Journal of Urology"},{"key":"10.1016\/j.urolonc.2022.05.013_bib0085","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44027","article-title":"Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System","volume":"5","author":"Yamoah","year":"2022","journal-title":"JAMA Network Open"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922001855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922001855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:02:27Z","timestamp":1777608147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143922001855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":85,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1078143922001855"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.05.013","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune mechanisms and molecular therapeutic strategies to enhance immunotherapy in non\u2013muscle invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}